G
Giulia Baciarello
Researcher at Institut Gustave Roussy
Publications - 51
Citations - 976
Giulia Baciarello is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 12, co-authored 46 publications receiving 587 citations. Previous affiliations of Giulia Baciarello include Université Paris-Saclay & University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
Karim Fizazi,Aline Maillard,Nicolas Penel,Giulia Baciarello,D. Allouache,Gedske Daugaard,A.J. van de Wouw,G. Soler,Elodie Vauleon,Loic Chaigneau,R. Janssen,F. Losa Gaspa,R. Morales Barrera,Carmen Balana,Diego Tosi,Bruno Chauffert,Catherine A. Schnabel,Geraldine Martineau,Stéphane Culine,Isabelle Borget +19 more
TL;DR: Using a molecular test followed by tailored systemic treatment did not improve outcomes of pts with CUP, and results suggest that at least 1/3 of identified primaries may not be sensitive to empiric chemotherapy used in CUPs.
Journal ArticleDOI
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
Laurence Albiges,Stéphanie Foulon,Arnaud Bayle,Bertrand Gachot,Fanny Pommeret,Christophe Willekens,Annabelle Stoclin,Mansouria Merad,Frank Griscelli,Ludovic Lacroix,Florence Netzer,Thomas Hueso,Corinne Balleyguier,Samy Ammari,Emeline Colomba,Giulia Baciarello,A. Perret,Antoine Hollebecque,Julien Hadoux,Jean-Marie Michot,Nathalie Chaput,Véronique Saada,Mathilde Hauchecorne,Jean Baptiste Micol,Roger Sun,Dominique Valteau-Couanet,Fabrice Andre,Florian Scotté,Benjamin Besse,Jean-Charles Soria,Fabrice Barlesi,Fabrice Barlesi +31 more
TL;DR: COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of Patients.
Journal ArticleDOI
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
Julie N. Graff,Julie N. Graff,Giulia Baciarello,Andrew J. Armstrong,Celestia S. Higano,Peter Iversen,Thomas W. Flaig,David Forer,Teresa Parli,De Phung,Bertrand Tombal,Tomasz M. Beer,Cora N. Sternberg +12 more
TL;DR: Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS and were well tolerated in the elderly subgroup and those aged <75 years, and age and enzyme treatment were associated with a higher incidence of falls.
Journal ArticleDOI
Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
François-Xavier Danlos,Claudia Grajeda-Iglesias,Sylvère Durand,Allan Sauvat,Mathilde Roumier,Delphine Cantin,Emeline Colomba,Julien Rohmer,Fanny Pommeret,Giulia Baciarello,Christophe Willekens,Marc Vasse,Frank Griscelli,Jean-Eudes Fahrner,Jean-Eudes Fahrner,Anne-Gaëlle Goubet,Anne-Gaëlle Goubet,Agathe Dubuisson,Agathe Dubuisson,Lisa Derosa,Lisa Derosa,Nitharsshini Nirmalathasan,Delphine Bredel,Severine Mouraud,Caroline Pradon,Annabelle Stoclin,Flore Rozenberg,Jérôme Duchemin,Georges Jourdi,Syrine Ellouze,Françoise Levavasseur,Laurence Albiges,Jean-Charles Soria,Fabrice Barlesi,Fabrice Barlesi,Eric Solary,Fabrice Andre,Fabrice Andre,Frédéric Pène,Félix Ackerman,Luc Mouthon,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Aurélien Marabelle,Jean-Marie Michot,Michaela Fontenay,Guido Kroemer +47 more
TL;DR: In this paper, the authors report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care).
Journal ArticleDOI
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.
F. Ruatta,Lisa Derosa,Bernard Escudier,Emeline Colomba,A. Guida,Giulia Baciarello,Yohann Loriot,Karim Fizazi,Laurence Albiges +8 more
TL;DR: This study suggests that MSKCC score, numbers of BMs and radical resection are important prognostic factors for RCC patients with BMs, and in the presence of solitary BM without concomitant metastases, bone surgery should be considered to achieve local tumour control and likely increase OS.